Leading global clinical research institute joins clinical trial for 'acute myeloid leukemia'
[by Kang, In Hyo] SillaJen announced on April 3 that five prominent cancer research institutions in the U.S., including MD Anderson Cancer Center, Yale Cancer Center, and Montefiore Einstein Comprehensive Cancer Center, along with one institution in Korea, will participate in the clinical trial of ‘BAL0891,’ an anticancer drug candidate for the treatment of acute myeloid leukemia (AML).
The company stated that these institutions were recently registered as participants on ClinicalTrials, a global clinical trial registry. 스피드 바카라 is a first-in-class dual inhibitor anticancer drug candidate designed to simultaneously inhibit ‘TTK (Threonine Tyrosine Kinase)’ and ‘PLK1 (Polo-Like Kinase 1)’. In addition, studies targeting various solid tumors are currently being conducted in both Korea and the United States.
SillaJen recently submitted an Investigational New Drug (IND) amendment application to the U.S. Food and Drug Administration (FDA) to expand the indication of 스피드 바카라 to include acute myeloid leukemia. 스피드 바카라 exerts a potent anticancer effect by simultaneously inhibiting two kinases, TTK and PLK1, which are essential for the cell division process in cancer cells, disrupting cancer cell division and inducing apoptosis.
Notably, in a preclinical study using the MOLM-14 acute myeloid leukemia transplant model, 스피드 바카라 demonstrated significant tumor growth inhibition and an improved survival rate, exhibiting anticancer efficacy even at low doses. Furthermore, when administered in combination with a ‘BCL-2 inhibitor,’ a widely used therapeutic agent for acute myeloid leukemia, a synergistic effect was observed.
Building on these promising preclinical findings, SillaJen stated that globally recognized clinical research institutes, including MD Anderson Cancer Center and Yale Cancer Center, have chosen to actively participate in the trial. The company further emphasized that the participation of these institutions is expected to enhance the clinical credibility and global competitiveness of 스피드 바카라.
This phase 1 clinical trial aims to assess the safety of 스피드 바카라 as a monotherapy in patients with relapsed or refractory acute myeloid leukemia. Additionally, the study will establish the maximum tolerated dose (MTD) and determine the recommended clinical dose (RP2D).
“Acute myeloid leukemia is a representative form of blood cancer characterized by a high relapse rate and poor prognosis. However, we anticipate that 스피드 바카라’s dual inhibition mechanism will help overcome the limitations of existing treatments,” a SillaJen official expressed. “We are committed to continuous research and development (R&D) efforts to establish 스피드 바카라 as a leading innovative novel drug in the treatment of solid tumors and blood cancers.”
Conversely, 스피드 바카라 plans to initiate clinical trials for acute myeloid leukemia within the year. A portion of the preclinical study findings will be presented at an international academic conference in the first half of the year.